EIN 88-3068255

Securebio

IRS 501(c) type
501(c)(3)
Num. employees
8
Year formed
2022
Most recent tax filings
2023-12-01
Description
Securebio conducts research on pandemic prevention, detection, and mitigation. They develop gene synthesis screening software and detect metagenomic sequences in wastewater.
Total revenues
$4,319,125
2023
Total expenses
$2,853,790
2023
Total assets
$4,855,240
2023
Num. employees
8
2023

Program areas at Securebio

As part of its SecureDNA project, the organization made significant progress in 2023 on its gene synthesis screening software. The team released an alpha version and prepared for a public beta launch. This free software offers best-in-class performance in screening criteria and runs against a continuously updated hazard database. SecureDNA uniquely integrates with both vendor order flows and benchtop synthesizers. The organization successfully tested with major manufacturers and collaborated with leading gene synthesis companies in the US and China. Two papers were prepared for submission to Nature, one on the screening system and another on its cryptographic architecture. These advancements further the organization's goal of securely monitoring synthetic DNA orders against various public health hazards.
As part of its work on the FAR-UVC project, the organization conducted an in-depth examination of the safety of far-UVC germicidal light throughout 2023. This comprehensive study involved convening a group of experts for both in-person and remote workshops over a 12-month period. The culmination of this extensive research was the release of a major paper on far-UVC safety, effectively concluding the organization's work on this project. While the organization designed a clinical study to further investigate the application of far-UVC technology, it determined that executing such a trial was not feasible given the available resources. This decision marked the completion of the organization's active involvement in the FAR-UVC research initiative.
As part of its work on the Nucleic Acid Observatory (NAO) project, the organization runs experiments to detect metagenomic sequences in wasterwater, with the ultimate aim of detecting new diseases before they grow exponentially in the community. In 2023, The NAO team conducted a major experiment, collecting wastewater samples from a prominent US airport and one of the nation's largest wastewater treatment plants. This rich dataset is slated for analysis in the coming year. The team expanded its research output, publishing a paper on pathogen abundance as a function of disease prevalence, building upon their previous report on the topic. Additionally, they released a paper on virus-like phagemids, which were designed and built in-house to experimentally characterize wastewater-based pathogen monitoring systems. To accelerate disease detection capabilities in wastewater, the organization initiated work on a more immediate NAO pilot project, focusing on specific pathogens rather than the full-scale, pathogen-agnostic approach of the primary NAO initiative.

Who funds Securebio

Grants from foundations and other nonprofits
GrantmakerDescriptionAmount
Good Ventures FoundationResearch and Activities for Reducing Risks From Advanced Biotechnologies$1,420,937
Aphorism FoundationGeneral Support$1,160,000
Founders PledgeGeneral Support$548,000
...and 3 more grants received

Personnel at Securebio

NameTitleCompensation
Ben MuellerExecutive Director
Alvaro MoralesDirector of Operations
Tiffany TzengOperations Manager$116,071

Financials for Securebio

RevenuesFYE 12/2023
Total grants, contributions, etc.$4,245,450
Program services$18,529
Investment income and dividends$52,990
Tax-exempt bond proceeds$0
Royalty revenue$0
Net rental income$0
Net gain from sale of non-inventory assets$0
Net income from fundraising events$0
Net income from gaming activities$0
Net income from sales of inventory$0
Miscellaneous revenues$2,156
Total revenues$4,319,125

Form 990s for Securebio

Fiscal year endingDate received by IRSFormPDF link
2023-122024-11-15990View PDF
2023-122024-10-22990View PDF
2022-122023-11-15990View PDF
Data update history
March 24, 2025
Updated personnel
Identified 4 new personnel
January 12, 2025
Received grants
Identified 2 new grant, including a grant for $1,160,000 from Aphorism Foundation
December 6, 2024
Posted financials
Added Form 990 for fiscal year 2023
November 27, 2024
Used new vendors
Identified 4 new vendors, including , , , and
September 21, 2024
Received grants
Identified 1 new grant, including a grant for $548,000 from Founders Pledge
Nonprofit Types
Research centersCharities
Issues
Science and technology
Characteristics
Conducts researchTax deductible donationsAccepts online donations
General information
Address
1 Broadway 13-100
Cambridge, MA 02142
Metro area
Boston-Cambridge-Newton, MA-NH
County
Middlesex County, MA
Website URL
securebio.org/ 
Phone
(615) 866-8656
IRS details
EIN
88-3068255
Fiscal year end
December
Taxreturn type
Form 990
Year formed
2022
Eligible to receive tax-deductible contributions (Pub 78)
Yes
Categorization
NTEE code, primary
U00: Science and Technology Research: General
NAICS code, primary
5417: Scientific Research and Development Services
Parent/child status
Independent
Free account sign-up

Want updates when Securebio has new information, or want to find more organizations like Securebio?

Create free Cause IQ account